Aims: This multicentre retrospective study describes HSCT characteristics and clinical outcomes of patients diagnosed with RUNX1 germline mutations during childhood who developed haematological diseases (from isolated thrombocytopenia to AML) and underwent HSCT by the age of 20. The gene discussed is RUNX1; the disease is Thrombocytopenia.